Bio-Path Holdings, Inc. is making waves in the field of oncology-focused RNAi nano particle drug development in the United States. Utilizing groundbreaking technology, the company's products are based on DNAbilize, which uses P-ethoxy, a DNA backbone modification that provides protective properties. The lead drug candidate, prexigebersen, is showing promising results in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Alongside this, the company is developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3, which is in preclinical stages aimed at treating pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. With a foundation dating back to 2007, Bio-Path Holdings, Inc.is headquartered in Bellaire, Texas, and serves as a beacon of innovation for the entire oncology community.